149 related articles for article (PubMed ID: 2632258)
1. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
2. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
3. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
4. Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days.
Chollet J; Mermelstein F; Rocamboli SC; Friend DR
Int J Pharm; 2019 Oct; 570():118691. PubMed ID: 31518632
[TBL] [Abstract][Full Text] [Related]
5. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
Poon GK; Walter B; Lønning PE; Horton MN; McCague R
Drug Metab Dispos; 1995 Mar; 23(3):377-82. PubMed ID: 7628304
[TBL] [Abstract][Full Text] [Related]
6. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
[TBL] [Abstract][Full Text] [Related]
7. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Kisanga ER; Gjerde J; Guerrieri-Gonzaga A; Pigatto F; Pesci-Feltri A; Robertson C; Serrano D; Pelosi G; Decensi A; Lien EA
Clin Cancer Res; 2004 Apr; 10(7):2336-43. PubMed ID: 15073109
[TBL] [Abstract][Full Text] [Related]
10. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.
Kisanga ER; Mellgren G; Lien EA
Anticancer Res; 2005; 25(6C):4487-92. PubMed ID: 16334131
[TBL] [Abstract][Full Text] [Related]
11. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
12. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
Langan-Fahey SM; Tormey DC; Jordan VC
Eur J Cancer; 1990; 26(8):883-8. PubMed ID: 2145931
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.
Osborne CK; Wiebe VJ; McGuire WL; Ciocca DR; DeGregorio MW
J Clin Oncol; 1992 Feb; 10(2):304-10. PubMed ID: 1732430
[TBL] [Abstract][Full Text] [Related]
15. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
Lien EA; Solheim E; Lea OA; Lundgren S; Kvinnsland S; Ueland PM
Cancer Res; 1989 Apr; 49(8):2175-83. PubMed ID: 2702659
[TBL] [Abstract][Full Text] [Related]
16. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives.
Gamboa da Costa G; McDaniel-Hamilton LP; Heflich RH; Marques MM; Beland FA
Carcinogenesis; 2001 Aug; 22(8):1307-15. PubMed ID: 11470763
[TBL] [Abstract][Full Text] [Related]
17. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen.
Gottardis MM; Robinson SP; Jordan VC
J Steroid Biochem; 1988; 30(1-6):311-4. PubMed ID: 3386259
[TBL] [Abstract][Full Text] [Related]
18. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
[TBL] [Abstract][Full Text] [Related]
19. Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
J Steroid Biochem; 1987 Dec; 28(6):609-18. PubMed ID: 3695512
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
